Infectious Disease Control
Vela Diagnostics Supports COVID-19 Surveillance Efforts in Kenya
HAMBURG, Germany, Aug. 3, 2022 /PRNewswire/ -- Vela Diagnostics has announced its appointment by the National Public Health Laboratory ofKenya (NPHL) as their supplier for SARS-CoV-2 genotyping tests, with funding from The Global Fund. The NPHL operates under Kenya's Ministry of Health and plays...
2022-08-03 14:00
2427
Novel and fast typing method developed to control monkeypox by Molecular Biology Systems (MBS) in collaboration with the Amsterdam UMC and Danish Rigshospitalet
GOES, Netherlands, Aug. 2, 2022 /PRNewswire/ -- In the worldwide effort to control monkeypox, a novel and fast typing method to trace monkeypox virus strains was developed by Dutch company Molecular Biology Systems (MBS) in collaboration with the department of Medical Microbiology & Infectious Di...
2022-08-02 08:00
2701
PERSISTENT LOSS OF SMELL DUE TO COVID-19 CLOSELY CONNECTED TO LONG-LASTING COGNITIVE PROBLEMS
FROM THE ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE 2022 Also, ICU Stay May Double Risk of Dementia in Older Adults SAN DIEGO, Aug. 1, 2022 /PRNewswire/ -- New insights into factors that may predict, increase or protect against the impact of COVID-19 and the pandemic on memory and thinkin...
2022-08-01 09:03
3056
Global Fund Reports Significant Progress in Breaking Down Human Rights-Related Barriers to HIV and TB Services
MONTREAL, Aug. 1, 2022 /PRNewswire/ -- A new report
2022-08-01 08:59
2133
Brii Biosciences Announces Positive Data Demonstrating its Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, Retains Neutralizing Activity Against Live Omicron Virus BA.4/5 and BA.2.12.1 Subvariants
Independent lab results demonstrate that the combination therapy retains neutralizing activity against currently dominant COVID-19 strains, as previously demonstrated with all variants of concern to date The amubarvimab/romlusevimab combination is commercially available in China and is under rev...
2022-07-27 07:00
3862
Novavax Announces Expanded Approval of Nuvaxovid™ COVID-19 Vaccine for Adolescents Aged 12 through 17 in Japan
* Nuvaxovid™ is the first protein-based COVID-19 vaccine approved for use in adolescents inJapan GAITHERSBURG, Md., July 26, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious d...
2022-07-26 20:05
2786
Vaccines alone aren't enough to combat AMR, claims new WHO report
The Global Hygiene Council (GHC) calls for the use of hygiene practices, such
as handwashing, alongside vaccinations to prevent the spread of infectious
diseases and reduce the impact of antimicrobial resistance (AMR).
LONDON, July 23, 2022 /PRNewswire/ -- A recent report
2022-07-23 00:30
8936
VIRALEZE™ Nasal Spray Protects Against Highly Infectious Omicron in Viral Challenge Model - Before or After Viral Exposure
MELBOURNE, Australia, July 20, 2022 /PRNewswire/ -- Starpharma's broad-spectrum VIRALEZE™ nasal spray has shown protection against infection with the highly transmissible SARS-CoV-2 Omicron variant in a stringent viral challenge model. VIRALEZE™ is a broad-spectrum barrier nasal spray, developed ...
2022-07-20 17:45
2261
U.S. CDC Advisory Committee Unanimously Recommends Novavax COVID-19 Vaccine, Adjuvanted as a Primary Series for Individuals Aged 18 and Older
* Recommendation follows U.S. FDA Emergency Use Authorization for the Novavax COVID-19 Vaccine, Adjuvanted as a two-dose primary series * FDA has determined that first vaccine lot has met all release specifications and is acceptable for use underEmergency Use Authorization * Novavax expects ...
2022-07-20 05:46
2995
Seegene launches world's first In-life PCR campaign in Vietnam
* Test center LabHouse and ride-hailing service Grab to start PCR testing for Grab drivers in August * Seegene to provide Allplex™ SARS-CoV-2/FluA/FluB/RSV Assay to simultaneously detect COVID-19, flu, cold * Testing to begin with drivers in Ho Chi Minh, Hanoi and will later be expanded to ...
2022-07-19 18:43
2137
Brii Bio Announces Strategic Partnership with China Resources Pharmaceutical Commercial Group to Advance the Commercialization of Long-acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, in China
The partnership will accelerate stockpiling, channel distribution and hospital access for the amubarvimab/romlusevimab combination in China The amubarvimab/romlusevimab combination is the first locally-discovered and approved SARS-CoV-2 target-specific treatment inChina, evaluated through a rand...
2022-07-19 12:34
4423
Zymo Research's DNA/RNA Shield™ Inactivates Monkeypox for the Collection and Transportation of Samples
IRVINE, Calif., July 15, 2022 /PRNewswire/ -- Zymo Research Corp., in collaboration with the Institute of Virology, University Medical Center Freiburg,Germany, demonstrated data showing their DNA/RNA Shield™ Inactivating Transport Medium (ITM) completely inactivated recent Monkeypox virus isolate...
2022-07-15 06:42
4096
U.S. FDA Grants Emergency Use Authorization for Novavax COVID-19 Vaccine, Adjuvanted for Individuals Aged 18 and Over
* Novavax' vaccine is the first protein-based COVID-19 vaccine authorized in the U.S. * Immunizations with the Novavax COVID-19 Vaccine, Adjuvanted as a primary series will begin upon product release and once a policy recommendation from the CDC is received GAITHERSBURG, Md., July 14, 2022 /P...
2022-07-14 06:06
3443
Glenmark Pharmaceuticals and SaNOtize Announce Peer Reviewed Publication of Its Phase 3 Clinical Trials on SaNOtize's Novel Nitric Oxide Nasal Spray for COVID-19 in Lancet Journal
MUMBAI, India and VANCOUVER, BC, July 13, 2022 /PRNewswire/ -- Glenmark Pharmaceuticals Limited (Glenmark), an innovation-driven, global pharmaceutical company and SaNOtize Research and Development Corp, today announced thatThe Lancet Regional Health Southeast Asia (TLRHSEA) – peer reviewed, high...
2022-07-13 20:06
3446
Brii Biosciences Appoints Dr. Susannah Cantrell as Chief Business Officer
Strategic executive hire adds to Company's global leadership team and positions
the Company for continued growth
DURHAM, N.C.and BEIJING, July 13, 2022 /PRNewswire/ -- Brii Biosciences
Limited
2022-07-13 19:00
3396
U.S. Government Secures 3.2 Million Doses of Novavax COVID-19 Vaccine
* Agreement will provide the first protein-based vaccine option in the U.S., pending FDA Emergency Use Authorization and CDC recommendation GAITHERSBURG, Md. ,July 11, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-gene...
2022-07-11 20:10
4074
iGene Laboratory launches Monkeypox PCR test for the South East Asian region.
SINGAPORE, July 8, 2022 /PRNewswire/ -- iGene Laboratory, the molecular
diagnostics laboratory subsidiary of INEX Innovate Pte Ltd, announces the
launch of its research-use-only (RUO) polymerase chain reaction (PCR) Monkeypox
test in response to the recent outbreak of the virus.
2022-07-08 12:25
3587
Brii Biosciences Announces Commercial Launch of its Amubarvimab/Romlusevimab Combination Therapy for COVID-19 in China
The Company is working closely with its commercial partners to supply the combination therapy to patients in need Brii Bio progressed the combination therapy from discovery to global Phase 3 data readout and first regulatory approval by the China NMPA in less than 20 months, validating the Com...
2022-07-07 07:10
4466
Ascletis Announces U.S. IND Filing of Oral RdRp Inhibitor Drug Candidate ASC10 for COVID-19
-- ASC10 is an oral small molecule drug candidate, which is in-house discovered and developed, and Ascletis retains full global rights for its development and commercialization --This IND filing of ASC10 in the U.S. will accelerate Ascletis' global multi-center clinical studies on ASC10 and bett...
2022-07-06 08:10
4355
Novavax Nuvaxovid™ COVID-19 Vaccine Conditionally Authorized in the European Union for Adolescents Aged 12 Through 17
* Nuvaxovid™ COVID-19 vaccine is the first protein-based option for adolescents aged 12 through 17 inEurope GAITHERSBURG, Md., July 5, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious inf...
2022-07-05 23:37
3944
Week's Top Stories
Most Reposted
ABL Bio Receives Upfront Payment for License, Research and Collaboration Agreement for Grabody Platform and Equity Investment from Lilly
[Picked up by 278 media titles]
2025-12-26 12:55ACEN completes transition to 100% renewable energy
[Picked up by 273 media titles]
2025-12-29 18:53Vietnam's Newest EDM Destination, APLUS SAIGON, Debuts With Star-Studded Soft Opening Weekends Featuring Dombresky and Argy
[Picked up by 273 media titles]
2025-12-30 20:12
CYFIRMA's 2025 Impact Recap Showcases DeCYFIR, Preemptive External Threat Landscape Management Platform, Delivering Measurable Global Defense Against Emerging Threats
[Picked up by 262 media titles]
2025-12-29 09:00
ChinaAMC launches Depository Receipts of two Chinese flagship ETFs in Thai exchange
[Picked up by 259 media titles]
2025-12-29 14:27